Congress has voted to temporarily extend a sweeping tool that has helped federal agents crack down on drugs chemically similar to fentanyl.
The Senate on Thursday approved legislation extending until October an order that allows the federal government to classify so-called fentanyl analogues as Schedule I controlled substances. The drugs are generally foreign-made with a very close chemical makeup to the dangerous opioid.
The authority was set to expire next week. Some feared that letting the authorization lapse could have led to a surge in opioid deaths.
The Justice Department during President Donald Trump’s administration lobbied to make the ban permanent, putting fentanyl analogues in the same legal category as heroin and cocaine forever.
The legislation headed to President Joe Biden’s desk temporarily classifies the synthetic opioids as a Schedule I drug under the federal Controlled Substances Act, making it easier for prosecutors to build cases against traffickers. The emergency authority was initially authorized in 2018.
The temporary extension gives lawmakers several months to hammer out details of a more permanent solution and work through concerns with the mandatory minimum sentences attached to the order. The law triggers some mandatory penalties for possessing large quantities of fentanyl or fentanyl analogues.
The Biden administration had been slow-walking its work on the extension and had, on several occasions in recent weeks, canceled meetings with officials at the Drug Enforcement Administration to discuss the plan around fentanyl analogues, three people familiar with the matter told The Associated Press.
A White House spokesman told the AP that the Biden administration was “committed to avoiding expiration of this legislation.”
© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Congress passes extension of opioid enforcement tool (2021, April 29)
retrieved 29 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.